1. Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities.
- Author
-
Bogut, Ana, Stojanovic, Bojan, Jovanovic, Marina, Dimitrijevic Stojanovic, Milica, Gajovic, Nevena, Stojanovic, Bojana S., Balovic, Goran, Jovanovic, Milan, Lazovic, Aleksandar, Mirovic, Milos, Jurisevic, Milena, Jovanovic, Ivan, and Mladenovic, Violeta
- Subjects
- *
PANCREATIC duct , *BIOLOGY , *ADENOCARCINOMA , *IMMUNOREGULATION , *TUMOR growth , *PROGRAMMED cell death 1 receptors , *NANOMEDICINE - Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most challenging malignancies to treat, with a complex interplay of molecular pathways contributing to its aggressive nature. Galectin-1 (Gal-1), a member of the galectin family, has emerged as a pivotal player in the PDAC microenvironment, influencing various aspects from tumor growth and angiogenesis to immune modulation. This review provides a comprehensive overview of the multifaceted role of Galectin-1 in PDAC. We delve into its contributions to tumor stroma remodeling, angiogenesis, metabolic reprogramming, and potential implications for therapeutic interventions. The challenges associated with targeting Gal-1 are discussed, given its pleiotropic functions and complexities in different cellular conditions. Additionally, the promising prospects of Gal-1 inhibition, including the utilization of nanotechnology and theranostics, are highlighted. By integrating recent findings and shedding light on the intricacies of Gal-1's involvement in PDAC, this review aims to provide insights that could guide future research and therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF